Particle.news

TrumpRX.gov Launches With 40+ Lower-Priced Drugs as Companies Announce Cuts

The push leans on 'most favored nation' pricing to align U.S. costs with rates in other wealthy countries.

Overview

  • The government-linked TrumpRX.gov site has gone live, listing more than 40 medicines offered at lower prices for consumers.
  • Boehringer Ingelheim, Novartis, and Sanofi announced steep reductions on specific drugs, including Jentadueto ($525 to $55), Mayzent ($9,987 to $1,137), and Plavix ($756 to $16).
  • On Feb. 4, the administration and FTC Chair Andrew Ferguson reached a settlement with a pharmacy benefit manager that the coverage says will lower insulin prices and expand drugs covered under TrumpRx.
  • The effort follows letters sent last July to 17 large drugmakers and promotes a 'most favored nation' approach that ties U.S. prices to those paid in other developed countries.
  • Administration-aligned commentary reports manufacturer commitments to at least $150 billion in U.S. production and donations to a strategic API reserve, which have not been independently corroborated in the provided coverage.